In conclusion, the CHMP was of the opinion that the current weight of evidence is that the benefit-risk assessment remains favourable in this restricted target population indication of persistent aggression in Alzheimer’ s dementia for short-term treatment only (6 weeks) and with all restrictions and conditions indicated in the SPC.